Mega-mon­ey biotech round spills $116M in­to gene ther­a­py up­start Free­line

The mega-mon­ey pour­ing in­to biotechs isn’t re­strict­ed to the US. Uni­ver­si­ty Col­lege Lon­don spin­out Free­line just scored a $116 mil­lion Se­ries B, with heavy­weight health­care in­vestor Syn­cona pro­vid­ing the bulk of the cash.

Found­ed by UCL pro­fes­sor Amit Nath­wani three years ago, Free­line is mak­ing a rep­u­ta­tion for it­self in the boom­ing gene ther­a­py field. With teams in the UK and Ger­many, Free­line is build­ing AAV vec­tor tech to de­liv­er gene ther­a­pies to the liv­er, an­oth­er ex­am­ple of the once-and-done cu­ra­tive ap­proach that has at­tract­ed a bright spot­light of pub­lic at­ten­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER